Remazolam Combined with Sufentanil in the Treatment of HMGB1, Interleukin-6/10/17, Tumor Necrosis Factor in Patients Undergoing Thoracoscopic Surgery- α the Impact of Plasma Stress Response Indicators

Objective: This study explores the efficacy of remimazolam combined with sufentanil in managing anesthesia for patients undergoing thoracoscopic surgery. Methods: A simple random sampling method selected 178 patients from our hospital between May 2021 and May 2022. Patients were randomly divided into two groups: the control group (CG) received sufentanil alone, whereas the observation group (OG) received a combination of remimazolam and sufentanil. Pain mediators, inflammatory factors, and plasma stress response indicators were measured and compared preoperatively and at 1, 3, 12, 24, and 48 h postoperation. The occurrence of adverse reactions (ARs) postoperation was also monitored. Results: Out of 178 patients, two were excluded – one from the CG who underwent open surgery and one from the OG who voluntarily withdrew – resulting in 176 patients with a data recovery rate of 98.88%. Repeated measurement analysis of variance indicated significant differences in levels of prostaglandin E2, high mobility group proteins, interleukin-6/10/17, tumor necrosis factor α, adrenaline, norepinephrine, cortisol, and fasting blood glucose between groups and over time ( P < 0.05). No significant differences in AR incidence were observed between the groups ( P > 0.05). Conclusion: The combination of remimazolam and sufentanil effectively inhibits the release of pain mediators and inflammatory factors in patients undergoing thoracoscopic surgery, alleviates postoperative stress responses, and demonstrates acceptable safety.